# Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

> **NCT06450106** · PHASE1 · RECRUITING · sponsor: **SURGE Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** STM-416p

## Key facts

- **NCT ID:** NCT06450106
- **Lead sponsor:** SURGE Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-08
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06450106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06450106, "Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy". Retrieved via AI Analytics 2026-07-22 from https://api.ai-analytics.org/clinical/NCT06450106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*